Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

UMA BORATE

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1619182946
CMS profile
209173
Location
COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$57,005.34

62 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $49,991.00 16
Travel and Lodging $5,068.56 19
Food and Beverage $1,945.78 27

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

UMA BORATE

NPI 1619182946 · CMS profile ID 209173

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619182946?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
UMA BORATE, NPI 1619182946, CMS profile ID 209173. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619182946?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). UMA BORATE, NPI 1619182946, CMS profile ID 209173. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619182946?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
UMA BORATE, NPI 1619182946, CMS profile ID 209173, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619182946?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

62 matching records · $57,005.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 62 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–62 of 62.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $66.8204/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1197009347 CMS
Rigel Pharmaceuticals, Inc. $36.1704/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247372129 CMS
Daiichi Sankyo Inc. $106.9602/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197039229 CMS
Daiichi Sankyo Inc. $641.8202/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1197039231 CMS
Daiichi Sankyo Inc. $20.0102/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197039233 CMS
Daiichi Sankyo Inc. $20.7102/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197048867 CMS
Daiichi Sankyo Inc. $689.1702/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1197097883 CMS
ABBVIE INC. $4,050.0002/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201541048 CMS
Genmab U.S., Inc. $785.0002/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1235929407 CMS
E.R. Squibb & Sons, L.L.C. $2,387.5001/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184655511 CMS
Astellas Pharma US Inc $2,775.5001/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238568275 CMS
Geron Corporation $1,600.0001/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238887168 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,274.78 37
PY2020 $37,714.25 23
PY2021 $35,805.00 15
PY2022 $41,292.45 31
PY2023 $60,031.56 63
PY2024 $57,381.41 80
PY2025 $57,005.34 62

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,000.00 1
PY2025 Principal investigator $9,315,054.29 382
PY2024 Principal investigator $4,670,258.91 33
PY2023 Recipient $872.18 2
PY2023 Principal investigator $4,282,737.08 31
PY2022 Recipient $1,000.00 1
PY2022 Principal investigator $1,997,046.18 57
PY2021 Recipient $7,890.85 6
PY2021 Principal investigator $253,142.70 37
PY2020 Recipient $4,728.93 4
PY2020 Principal investigator $1,295,851.56 137
PY2019 Principal investigator $1,637,212.39 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

383 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Geron Corporation $630.00 12/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238897186
Principal investigator 1 Geron Corporation $750.00 12/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238897190
Principal investigator 1 Geron Corporation $4,000.00 12/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238897192
Principal investigator 1 Geron Corporation $750.00 12/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238897196
Principal investigator 1 SANOFI US SERVICES INC. $27,495.00 12/15/2025 Non-covered Recipient Entity
The Ohio State University The Ohio State University
FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC No dispute reported 06/30/2026 1226096386
Principal investigator 1 SANOFI US SERVICES INC. $3,380.00 12/15/2025 Non-covered Recipient Entity
The Ohio State University The Ohio State University
FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC No dispute reported 06/30/2026 1226096392
Principal investigator 1 Daiichi Sankyo Inc. $410.00 12/12/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375405
Principal investigator 1 Daiichi Sankyo Inc. $1,710.00 12/12/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375407
Principal investigator 1 Daiichi Sankyo Inc. $17,790.00 12/12/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375409
Principal investigator 1 Daiichi Sankyo Inc. $5,010.00 12/12/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375411
Principal investigator 1 Daiichi Sankyo Inc. $5,000.00 12/12/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375413
Principal investigator 1 Daiichi Sankyo Inc. $3,503.00 12/12/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375415
Principal investigator 1 TAIHO ONCOLOGY, INC. $98,640.00 12/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420121
Principal investigator 1 SANOFI US SERVICES INC. $3,980.60 12/08/2025 Non-covered Recipient Entity
The Ohio State University The Ohio State University
FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC No dispute reported 06/30/2026 1226096371
Principal investigator 1 SANOFI US SERVICES INC. $10,831.82 12/08/2025 Non-covered Recipient Entity
The Ohio State University The Ohio State University
FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC No dispute reported 06/30/2026 1226096378
Principal investigator 1 Sumitomo Pharma America, Inc. $9,562.00 12/04/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656956
Principal investigator 1 Sumitomo Pharma America, Inc. $4,200.00 12/04/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656961
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $59,793.91 12/03/2025 Non-covered Recipient Entity
Ohio State University Resear Fo
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1235994990
Principal investigator 1 Incyte Corporation $16,089.08 12/03/2025 Non-covered Recipient Entity
The Ohio State University
A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms No dispute reported 06/30/2026 1240602586
Principal investigator 1 Novartis Pharmaceuticals Corporation $20.00 12/01/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY
Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria No dispute reported 06/30/2026 1190305193
Principal investigator 1 TAIHO ONCOLOGY, INC. $85,610.00 11/11/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418671
Principal investigator 1 Astellas Pharma Global Development $109.00 11/07/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186727
Principal investigator 1 Astellas Pharma Global Development $285.00 11/07/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186729
Principal investigator 1 Astellas Pharma Global Development $260.00 11/07/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186731
Principal investigator 1 Astellas Pharma Global Development $260.00 11/07/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186733
Principal investigator 1 Astellas Pharma Global Development $260.00 11/07/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186735
Principal investigator 1 Astellas Pharma Global Development $109.00 11/07/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186737
Principal investigator 1 Incyte Corporation $72,400.88 11/04/2025 Non-covered Recipient Entity
The Ohio State University
A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms No dispute reported 06/30/2026 1240602582
Principal investigator 1 TAIHO ONCOLOGY, INC. $9,500.00 10/29/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415860
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,600.00 10/29/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415862
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $47,162.78 10/28/2025 Non-covered Recipient Entity
The Ohio State University
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms No dispute reported 06/30/2026 1233745004
Principal investigator 1 Geron Corporation $4,000.00 10/27/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896365
Principal investigator 1 Sumitomo Pharma America, Inc. $360.00 10/27/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY CLINICAL TRIALS OFFICE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176651674
Principal investigator 1 Sumitomo Pharma America, Inc. $157.51 10/23/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176651462
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186739
Principal investigator 1 Astellas Pharma Global Development $2,818.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186741
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186743
Principal investigator 1 Astellas Pharma Global Development $2,829.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186745
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186747
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186749
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186751
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186753
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186755
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186757
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186759
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186761
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186763
Principal investigator 1 Astellas Pharma Global Development $2,818.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186765
Principal investigator 1 Astellas Pharma Global Development $2,818.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186767
Principal investigator 1 Astellas Pharma Global Development $3,003.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186769
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186771
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186773
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186775
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186777
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186779
Principal investigator 1 Astellas Pharma Global Development $3,003.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186781
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186783
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186785
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186787
Principal investigator 1 Astellas Pharma Global Development $3,881.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186789
Principal investigator 1 Astellas Pharma Global Development $3,881.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186791
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186793
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186795
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186797
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186799
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186801
Principal investigator 1 Astellas Pharma Global Development $2,829.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186803
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186805
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186807
Principal investigator 1 Astellas Pharma Global Development $2,818.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186809
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186811
Principal investigator 1 Astellas Pharma Global Development $2,818.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186813
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186815
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186817
Principal investigator 1 Astellas Pharma Global Development $1,541.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186819
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186821
Principal investigator 1 Astellas Pharma Global Development $3,003.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186823
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186825
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186827
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186829
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186831
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186833
Principal investigator 1 Astellas Pharma Global Development $2,818.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186835
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186837
Principal investigator 1 Astellas Pharma Global Development $3,881.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186839
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186841
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186843
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186845
Principal investigator 1 Astellas Pharma Global Development $1,281.80 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186847
Principal investigator 1 Astellas Pharma Global Development $2,907.00 10/22/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186849
Principal investigator 1 TAIHO ONCOLOGY, INC. $5,960.00 10/17/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417961
Principal investigator 1 Geron Corporation $1,081.51 10/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896222
Principal investigator 1 Geron Corporation $1,081.51 10/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896226
Principal investigator 1 Geron Corporation $1,081.51 10/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896230
Principal investigator 1 Geron Corporation $1,081.51 10/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896233
Principal investigator 1 Geron Corporation $1,081.51 10/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896237
Principal investigator 1 Geron Corporation $1,081.51 10/15/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896242
Principal investigator 1 ABBVIE INC. $832.64 10/14/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) No dispute reported 06/30/2026 1202516767
Principal investigator 1 ABBVIE INC. $2,082.88 10/14/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) No dispute reported 06/30/2026 1202516769
Principal investigator 1 ABBVIE INC. $8,329.60 10/14/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) No dispute reported 06/30/2026 1202516771
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 10/08/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 1223262740
Principal investigator 1 Servier BioInnovation $17,800.00 10/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) No dispute reported 06/30/2026 1235975075
Principal investigator 1 Servier BioInnovation $5,000.00 10/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) No dispute reported 06/30/2026 1235975078
Principal investigator 1 Servier BioInnovation $6,000.00 10/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) No dispute reported 06/30/2026 1235975082
Principal investigator 1 Servier BioInnovation $4,060.00 10/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) No dispute reported 06/30/2026 1235975086
Principal investigator 1 Servier BioInnovation $470.00 10/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) No dispute reported 06/30/2026 1235975091
Principal investigator 1 Servier BioInnovation $1,950.00 10/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH) No dispute reported 06/30/2026 1235975094
Principal investigator 1 Sumitomo Pharma America, Inc. $2,240.00 10/02/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176650445
Principal investigator 1 TAIHO ONCOLOGY, INC. $34,430.00 09/25/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417259
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,589.96 09/18/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY
A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome No dispute reported 06/30/2026 1190305197
Principal investigator 1 ABBVIE INC. $62,472.00 09/15/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) No dispute reported 06/30/2026 1202510964
Principal investigator 1 ABBVIE INC. $8,329.60 09/15/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) No dispute reported 06/30/2026 1202510966
Principal investigator 1 Sumitomo Pharma America, Inc. $12,616.78 09/04/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176647180
Principal investigator 1 TAIHO ONCOLOGY, INC. $37,000.00 09/01/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417965
Principal investigator 1 ABBVIE INC. $1,248.96 08/28/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) No dispute reported 06/30/2026 1202506517
Principal investigator 1 TAIHO ONCOLOGY, INC. $17,323.44 08/25/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
ASTX727-07 No dispute reported 06/30/2026 1211416578
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,950.00 08/25/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
ASTX727-07 No dispute reported 06/30/2026 1211417963
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,008.00 08/25/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
ASTX727-07 No dispute reported 06/30/2026 1211419373
Principal investigator 1 ABBVIE INC. $46,854.00 08/14/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS) No dispute reported 06/30/2026 1202504951
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,450.00 07/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419371
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,500.00 07/28/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418673
Principal investigator 1 TAIHO ONCOLOGY, INC. $9,650.00 07/28/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420119
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $35,924.20 07/22/2025 Covered Recipient Teaching Hospital
Arthur G James Cancer Hospital
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1236001829
Principal investigator 1 ABBVIE INC. $46,854.00 07/17/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia No dispute reported 06/30/2026 1202498830
Principal investigator 1 ABBVIE INC. $624.48 07/17/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia No dispute reported 06/30/2026 1202498832
Principal investigator 1 ABBVIE INC. $6,247.20 07/17/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia No dispute reported 06/30/2026 1202498834
Principal investigator 1 Incyte Corporation $15,594.00 07/15/2025 Non-covered Recipient Entity
The Ohio State University
Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS overlap or High-Risk CMML No dispute reported 06/30/2026 1240602557
Principal investigator 1 TAIHO ONCOLOGY, INC. $24,100.00 07/01/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420117
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,618.24 06/23/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
ASTX727-07 No dispute reported 06/30/2026 1211415153
Principal investigator 1 TAIHO ONCOLOGY, INC. $254.59 06/23/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
ASTX727-07 No dispute reported 06/30/2026 1211418679
Principal investigator 1 Sumitomo Pharma America, Inc. $12,000.00 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636536
Principal investigator 1 Sumitomo Pharma America, Inc. $1,467.69 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636539
Principal investigator 1 Incyte Corporation $6,565.00 06/13/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib No dispute reported 06/30/2026 1240602719
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,805,351.00 06/12/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY
Inflammation Modification to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Signicance Trial (IMPACT) No dispute reported 06/30/2026 1190305191
Principal investigator 1 Incyte Corporation $5,198.00 06/10/2025 Non-covered Recipient Entity
The Ohio State University
Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS overlap or High-Risk CMML No dispute reported 06/30/2026 1240602552
Principal investigator 1 Sumitomo Pharma America, Inc. $270.06 06/05/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176635995
Principal investigator 1 Sumitomo Pharma America, Inc. $81.02 06/05/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176635999
Principal investigator 1 Sumitomo Pharma America, Inc. $23,800.15 06/05/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636003
Principal investigator 1 Sumitomo Pharma America, Inc. $6,962.00 06/05/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636006
Principal investigator 1 Astellas Pharma Global Development $2,907.00 06/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186719
Principal investigator 1 Astellas Pharma Global Development $2,907.00 06/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186721
Principal investigator 1 Astellas Pharma Global Development $2,907.00 06/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186723
Principal investigator 1 Astellas Pharma Global Development $2,907.00 06/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186725
Principal investigator 1 TAIHO ONCOLOGY, INC. $13,630.00 06/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418677
Principal investigator 1 Astellas Pharma Global Development $1,541.00 05/26/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186696
Principal investigator 1 Astellas Pharma Global Development $1,541.00 05/26/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186715
Principal investigator 1 Geron Corporation $750.00 05/16/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY OFFICE OF SPONSORED PROGRAMS
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895215
Principal investigator 1 ABBVIE INC. $10,414.40 05/12/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
A20-256;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets No dispute reported 06/30/2026 1202484667
Principal investigator 1 ABBVIE INC. $8,326.40 05/12/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
A20-256;Venclexta;Blister Card: ABT-199 10mg Tablet 2x8, 16 Tablets No dispute reported 06/30/2026 1202484669
Principal investigator 1 Astellas Pharma Global Development $260.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186682
Principal investigator 1 Astellas Pharma Global Development $3,881.80 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186684
Principal investigator 1 Astellas Pharma Global Development $3,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186686
Principal investigator 1 Astellas Pharma Global Development $260.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186688
Principal investigator 1 Astellas Pharma Global Development $9,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186690
Principal investigator 1 Astellas Pharma Global Development $3,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186692
Principal investigator 1 Astellas Pharma Global Development $12,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186694
Principal investigator 1 Astellas Pharma Global Development $3,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186698
Principal investigator 1 Astellas Pharma Global Development $6,202.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186700
Principal investigator 1 Astellas Pharma Global Development $3,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186702
Principal investigator 1 Astellas Pharma Global Development $9,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186704
Principal investigator 1 Astellas Pharma Global Development $9,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186706
Principal investigator 1 Astellas Pharma Global Development $9,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186709
Principal investigator 1 Astellas Pharma Global Development $3,881.80 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186711
Principal investigator 1 Astellas Pharma Global Development $3,881.80 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186713
Principal investigator 1 Astellas Pharma Global Development $3,000.00 05/09/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186717
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186380
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186382
Principal investigator 1 Astellas Pharma Global Development $2,818.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186384
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186392
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186394
Principal investigator 1 Astellas Pharma Global Development $2,907.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186396
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186398
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186400
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186402
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186404
Principal investigator 1 Astellas Pharma Global Development $3,003.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186406
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186408
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186410
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186412
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186414
Principal investigator 1 Astellas Pharma Global Development $2,818.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186416
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186418
Principal investigator 1 Astellas Pharma Global Development $2,907.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186420
Principal investigator 1 Astellas Pharma Global Development $2,818.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186422
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186424
Principal investigator 1 Astellas Pharma Global Development $3,881.80 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186426
Principal investigator 1 Astellas Pharma Global Development $2,818.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186428
Principal investigator 1 Astellas Pharma Global Development $3,003.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186430
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186432
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186434
Principal investigator 1 Astellas Pharma Global Development $1,281.80 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186436
Principal investigator 1 Astellas Pharma Global Development $1,035.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186438
Principal investigator 1 Astellas Pharma Global Development $2,818.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186442
Principal investigator 1 Astellas Pharma Global Development $2,907.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186444
Principal investigator 1 Astellas Pharma Global Development $2,818.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186446
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186448
Principal investigator 1 Astellas Pharma Global Development $1,541.00 04/30/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186450
Principal investigator 1 ABBVIE INC. $26,036.00 04/28/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
A20-256;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets No dispute reported 06/30/2026 1202479797
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,400.00 04/28/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415151
Principal investigator 1 TAIHO ONCOLOGY, INC. $38,820.00 04/28/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416580
Principal investigator 1 TAIHO ONCOLOGY, INC. $72,300.00 04/28/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417969
Principal investigator 1 TAIHO ONCOLOGY, INC. $64,690.00 04/28/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417971
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,400.00 04/28/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418675
Principal investigator 1 TAIHO ONCOLOGY, INC. $12,600.00 04/28/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419375
Principal investigator 1 TAIHO ONCOLOGY, INC. $15,200.00 04/17/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415149
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,400.00 04/17/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417967
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,945.00 04/08/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (STIMULUS-MD No dispute reported 06/30/2026 1190299831
Principal investigator 1 Astellas Pharma Global Development $1,491.00 04/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186374
Principal investigator 1 Astellas Pharma Global Development $2,860.00 04/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186376
Principal investigator 1 Astellas Pharma Global Development $6,000.00 04/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186378
Principal investigator 1 Astellas Pharma Global Development $1,076.00 04/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186386
Principal investigator 1 Astellas Pharma Global Development $3,881.80 04/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186388
Principal investigator 1 Astellas Pharma Global Development $6,485.00 04/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186390
Principal investigator 1 Astellas Pharma Global Development $2,600.00 04/02/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186440
Principal investigator 1 SANOFI US SERVICES INC. $30,190.90 04/02/2025 Non-covered Recipient Entity
The Ohio State University
FIH STUDY - Combo - Master Protocol for Combotherapy IV+SC No dispute reported 06/30/2026 1226135824
Principal investigator 1 Sumitomo Pharma America, Inc. $1,101.09 03/27/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176630843
Principal investigator 1 Sumitomo Pharma America, Inc. $54.00 03/27/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176630847
Principal investigator 1 Astellas Pharma Global Development $305.76 03/25/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186454
Principal investigator 1 Astellas Pharma Global Development $2,907.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186452
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186456
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186458
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186460
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186462
Principal investigator 1 Astellas Pharma Global Development $3,003.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186464
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186466
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186468
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186470
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186472
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186474
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186476
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186478
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186480
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186482
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186484
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186486
Principal investigator 1 Astellas Pharma Global Development $3,881.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186488
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186490
Principal investigator 1 Astellas Pharma Global Development $2,829.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186492
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186494
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186496
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186498
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186500
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186502
Principal investigator 1 Astellas Pharma Global Development $3,881.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186504
Principal investigator 1 Astellas Pharma Global Development $321.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186506
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186508
Principal investigator 1 Astellas Pharma Global Development $3,003.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186510
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186512
Principal investigator 1 Astellas Pharma Global Development $321.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186514
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186516
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186518
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186520
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186522
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186524
Principal investigator 1 Astellas Pharma Global Development $2,907.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186526
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186528
Principal investigator 1 Astellas Pharma Global Development $3,881.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186530
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186532
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186534
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186536
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186538
Principal investigator 1 Astellas Pharma Global Development $2,829.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186540
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186542
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186544
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186546
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186548
Principal investigator 1 Astellas Pharma Global Development $3,003.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186550
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186552
Principal investigator 1 Astellas Pharma Global Development $3,881.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186554
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186556
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186558
Principal investigator 1 Astellas Pharma Global Development $2,907.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186560
Principal investigator 1 Astellas Pharma Global Development $3,881.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186562
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186564
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186566
Principal investigator 1 Astellas Pharma Global Development $2,907.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186568
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186570
Principal investigator 1 Astellas Pharma Global Development $884.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186572
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186574
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186576
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186578
Principal investigator 1 Astellas Pharma Global Development $3,881.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186580
Principal investigator 1 Astellas Pharma Global Development $3,003.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186582
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186584
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186586
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186588
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186590
Principal investigator 1 Astellas Pharma Global Development $2,907.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186592
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186594
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186596
Principal investigator 1 Astellas Pharma Global Development $3,881.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186598
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186600
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186602
Principal investigator 1 Astellas Pharma Global Development $2,907.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186604
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186606
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186608
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186610
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186612
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186614
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186616
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186618
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186620
Principal investigator 1 Astellas Pharma Global Development $3,003.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186622
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186624
Principal investigator 1 Astellas Pharma Global Development $3,881.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186626
Principal investigator 1 Astellas Pharma Global Development $3,003.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186628
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186630
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186632
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186634
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186636
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186638
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186640
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186642
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186644
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186646
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186648
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186650
Principal investigator 1 Astellas Pharma Global Development $884.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186652
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186654
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186656
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186658
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186660
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186662
Principal investigator 1 Astellas Pharma Global Development $1,541.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186664
Principal investigator 1 Astellas Pharma Global Development $3,003.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186666
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186668
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186670
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186672
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186674
Principal investigator 1 Astellas Pharma Global Development $2,818.00 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186676
Principal investigator 1 Astellas Pharma Global Development $1,281.80 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186678
Principal investigator 1 Astellas Pharma Global Development $1,510.60 03/21/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186680
Principal investigator 1 Sumitomo Pharma America, Inc. $274.00 03/18/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY CLINICAL TRIALS OFFICE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176630549
Principal investigator 1 ABBVIE INC. $10,408.00 03/13/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
A20-256;Venclexta;Blister Card: ABT-199 10mg Tablet 2x8, 16 Tablets No dispute reported 06/30/2026 1202463843
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375417
Principal investigator 1 Daiichi Sankyo Inc. $150.45 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375419
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375421
Principal investigator 1 Daiichi Sankyo Inc. $24.95 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375423
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375425
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375427
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375429
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375431
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375433
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375435
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375437
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375439
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375441
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375443
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375445
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375447
Principal investigator 1 Daiichi Sankyo Inc. $124.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375449
Principal investigator 1 Daiichi Sankyo Inc. $124.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375451
Principal investigator 1 Daiichi Sankyo Inc. $12.75 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375453
Principal investigator 1 Daiichi Sankyo Inc. $150.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375455
Principal investigator 1 Daiichi Sankyo Inc. $29.25 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375457
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375459
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375461
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375463
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375465
Principal investigator 1 Daiichi Sankyo Inc. $69.30 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375467
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375469
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375471
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375473
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Non-covered Recipient Entity
Ohio State University
AC220-168 No dispute reported 06/30/2026 1223375475
Principal investigator 1 Sumitomo Pharma America, Inc. $4,000.00 02/27/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628625
Principal investigator 1 Sumitomo Pharma America, Inc. $28,388.03 02/27/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628629
Principal investigator 1 Sumitomo Pharma America, Inc. $2,390.00 02/27/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTER
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628633
Principal investigator 1 Celgene Corporation $67,322.58 02/21/2025 Non-covered Recipient Entity
Ohio State University
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222307157
Principal investigator 1 Sumitomo Pharma America, Inc. $338.00 02/14/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY CLINICAL TRIALS OFFICE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176627750
Principal investigator 1 ABBVIE INC. $52,072.00 02/04/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
A20-256;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets No dispute reported 06/30/2026 1202443881
Principal investigator 1 ABBVIE INC. $62,472.00 01/30/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
A20-256;Venclexta;Blister Card: ABT-199 100mg Film-coated Tablet 2x8, 16 Tablets No dispute reported 06/30/2026 1202443381
Principal investigator 1 ABBVIE INC. $83,296.00 01/28/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
A20-256;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets No dispute reported 06/30/2026 1202441747
Principal investigator 1 Astellas Pharma Global Development $6,500.00 01/27/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186366
Principal investigator 1 Astellas Pharma Global Development $650.00 01/24/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186368
Principal investigator 1 Astellas Pharma Global Development $650.00 01/24/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186370
Principal investigator 1 Astellas Pharma Global Development $650.00 01/24/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy No dispute reported 06/30/2026 1234186372
Principal investigator 1 Incyte Corporation $975.00 01/22/2025 Non-covered Recipient Entity
The Ohio State University
Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS overlap or High-Risk CMML No dispute reported 06/30/2026 1240602562
Principal investigator 1 Incyte Corporation $1,197.00 01/22/2025 Non-covered Recipient Entity
The Ohio State University
Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS overlap or High-Risk CMML No dispute reported 06/30/2026 1240602566
Principal investigator 1 ABBVIE INC. $83,296.00 01/21/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY - WEXNER MEDICAL CENTER
A20-256;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets No dispute reported 06/30/2026 1202440471
Principal investigator 1 Celgene Corporation $122,875.95 01/17/2025 Non-covered Recipient Entity
Ohio State University
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222307165
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $56,702.40 01/07/2025 Covered Recipient Teaching Hospital
Arthur G James Cancer Hospital
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1236001827
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,263.35 01/07/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome No dispute reported 06/30/2026 1190299835
Principal investigator 1 Novartis Pharmaceuticals Corporation $220.00 01/01/2025 Non-covered Recipient Entity
OHIO STATE UNIVERSITY
Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria No dispute reported 06/30/2026 1190305195